Mylan Announces Name Change for its Branded Products Subsidiary to Mylan BertekPITTSBURGH, June 15 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it will change the name of its branded subsidiary, currently known as Bertek Pharmaceuticals Inc., to Mylan Bertek Pharmaceuticals Inc.

The name change of the branded subsidiary reflects Mylan's continued commitment and focus on its brand business in anticipation of the launch of two significant proprietary products. APOKYN^™, the first and only therapy approved in the United States for the acute, intermittent treatment of hypomobility ("off" episodes) associated with advanced Parkinson's disease, is expected to enter the market by the end of July 2004. The company also submitted a New Drug Application to the Food and Drug Administration for nebivolol, as a new treatment option for the management of hypertension, in April 2004.

"Changing the name of our branded subsidiary to Mylan Bertek reflects our focus on our branded business and more importantly, our commitment to being recognized as a well balanced pharmaceutical company," said Robert J. Coury, Vice Chairman and CEO of Mylan Laboratories.

The Company's other subsidiaries, including Mylan Pharmaceuticals Inc, Mylan Technologies Inc., and UDL Laboratories, Inc., will retain the same names.

The name change is expected to become effective in mid-July of this year.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

This press release includes statements that constitute "forward-looking statements," including with regard to the planned name change and the anticipated product launches. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties regarding market acceptance and demand for the products; the possible negative effects of any interruption of manufacturing at the Company's facilities; the potential costs and product introduction delays that may result from use of legal, regulatory and legislative strategies by the Company's competitors; a delay or other impairment to effecting the corporate name change; and the other risks detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.
06/15/2004
CONTACT:
Media, Heather Bresch, +1-724-514-1800
or Investors, Kris King, +1-724-514-1800
both of Mylan Laboratories Inc.


Web site: http://www.mylan.com